Fibrobiologics Inc
Veridion Score
Composite trend over time
Why is FBLG moving today?
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for FBLG.
FBLG insider activity
Fibrobiologics Inc
No multi-insider buying cluster in the last 90 days
Net buying: $121K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-05 | 2026-03-04 | Khoja Hamid | Insider | buy | $0.38 | 30,000 | 61,250 | $11K | SEC Form 4 |
| 2026-03-04 | 2026-03-04 | O'HEERON PETE | Insider | buy | $0.38 | 15,872 | 5,958,147 | $6K | SEC Form 4 |
| 2026-03-04 | 2026-03-03 | O'HEERON PETE | Insider | buy | $0.41 | 18,200 | 5,942,275 | $7K | SEC Form 4 |
| 2026-03-04 | 2026-03-02 | O'HEERON PETE | Insider | buy | $0.35 | 17,428 | 5,924,075 | $6K | SEC Form 4 |
| 2026-03-03 | 2026-03-02 | Davis Jason | Insider | buy | $0.41 | 70,000 | 70,000 | $29K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 2 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moFBLG contract awards, year to date.
Public federal awards linked to this ticker.
FBLG lobbying filings, year to date.
Registered lobbying filings matched to Fibrobiologics Inc.